Literature DB >> 30446459

Use of delayed intervention for small renal masses initially managed with active surveillance.

Mohit Gupta1, Ridwan Alam2, Hiten D Patel2, Alice Semerjian2, Michael A Gorin2, Michael H Johnson2, Peter Chang3, Andrew A Wagner3, James M McKiernan4, Mohamad E Allaf2, Phillip M Pierorazio2.   

Abstract

INTRODUCTION: A number of patients who elect active surveillance of their small renal masses (≤4 cm) subsequently pursue delayed intervention (DI). The indications, timing, and rates of DI have not been well determined prospectively.
MATERIALS AND METHODS: Data from Delayed Intervention and Surveillance for Small Renal Masses, a prospective, multi-institutional registry was utilized to evaluate factors associated with DI between 2009 and 2018.
RESULTS: Of 371 patients enrolled in AS, 46 (12.4%) pursued DI. Patients who pursued DI spent a median 12 months on surveillance (interquartile range 5.5-23.6), had better functional status (P < 0.01), and had greater median growth rate vs. those who remained on surveillance (0.38 vs. 0.05, P < 0.001). Indications for intervention included growth rate >0.5 cm/y for 23 (50%) patients, patient preference for 22 (47.8%) patients, and qualification for renal transplant in 1 (2.2%) patient. Thirty-two patients (69.6%) underwent nephron-sparing surgery, 5 (10.9%) underwent radical nephrectomy, and 9 (19.6%) underwent percutaneous cryoablation. Renal mass biopsy was utilized in 37 (11.4%) and 15 (32.7%) patients in the AS and DI arms, respectively (P = 0.04). No patients experienced metastatic progression or died of kidney cancer.
CONCLUSIONS: As nearly 50% of patients pursue DI secondary to anxiety in the absence of clinical progression, comprehensive counseling is essential to determine if patients are suitable for a surveillance protocol. AS remains a safe initial management option for many patients but may not be a durable strategy for patients who are acceptable surgical candidates with an extended life expectancy. DI does not compromise oncologic outcomes or limit treatment options.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Active surveillance; Carcinoma; Kidney neoplasms; Renal cancer; Renal cell

Mesh:

Year:  2018        PMID: 30446459     DOI: 10.1016/j.urolonc.2018.10.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  6 in total

Review 1.  Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management.

Authors:  Andrew W Silagy; Alejandro Sanchez; Brandon J Manley; Karim Bensalah; Axel Bex; Jose A Karam; Börje Ljungberg; Brian Shuch; A Ari Hakimi
Journal:  Eur Urol Focus       Date:  2019-04-28

2.  Definitive treatment vs. active surveillance for small renal masses: Closing the preference gap.

Authors:  Kiran Sury; Phillip M Pierorazio
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 1.862

3.  Treatment on active surveillance of small renal masses: Progression vs. preference.

Authors:  Douglas Cheung; Jed Frankel; Pavinder Tut; Maria Komisarenko; Lisa Martin; Michael Jewett; Antonio Finelli
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 2.052

4.  Active Surveillance for Risk Stratification of All Small Renal Masses Lacking Predefined Clinical Criteria for Intervention.

Authors:  Arun R Menon; Ahmed A Hussein; Kristopher M Attwood; Tashionna White; Gaybrielle James; Bo Xu; Michael Petroziello; Charles L Roche; Eric C Kauffman
Journal:  J Urol       Date:  2021-03-29       Impact factor: 7.600

Review 5.  Quality of Life and Psychological Distress among Patients with Small Renal Masses.

Authors:  Liliana Vartolomei; Andrei Cotruș; Camelia Stanciu; Cristian Delcea; Marco Tozzi; Elena Lievore; Felice Crocetto; Francesco Del Giudice; Giuseppe Lucarelli; Matteo Muto; Matteo Ferro
Journal:  J Clin Med       Date:  2022-07-07       Impact factor: 4.964

Review 6.  Decision-making in active surveillance in kidney cancer: current trends and future urine and tissue markers.

Authors:  Sunil H Patel; Nirmish Singla; Phillip M Pierorazio
Journal:  World J Urol       Date:  2021-08-09       Impact factor: 4.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.